CompletedNot Applicable

MRD Detection by NGS in Pediatric B-ALL

China430 participantsStarted 2018-11-01

Plain-language summary

This retrospective analysis aims to investigate pediatric patients with B-cell acute lymphoblastic leukemia who were detected for minimal residual disease (MRD) using next-generation sequencing (NGS). The study will utilize second-generation sequencing technology to analyze the rearrangement of the immunoglobulin heavy chain (IGH), immunoglobulin kappa light chain (IGK), and immunoglobulin lambda light chain (IGL) genes in these patients. Patients will be stratified based on NGS-MRD levels, and the relationship between NGS-MRD and Event-Free Survival (EFS) will be evaluated.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children with newly diagnosed B-ALL who undergone NGS of B-cell receptors * Children older than 1 year receive treatment according to the ZJCH-ALL-2019 protocol, while children younger than 1 year receive treatment according to the infant leukemia protocol. Exclusion Criteria: * B-cell acute lymphoblastic leukemia (B-ALL) patients who have not undergone high-throughput sequencing. * Treated according to other protocols.

What they're measuring

event-free survival

Timeframe: Between November 2018 and June 2022

Trial details

NCT IDNCT05973032

SponsorThe Children's Hospital of Zhejiang University School of Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-08-31

View on ClinicalTrials.gov More Acute Lymphoblastic Leukemia, Pediatric trials